Three PDXs were selected for their lack of PTEN expression by immunohistochemistry: a triple-negative breast cancer (TNBC), a <i>KRAS</i> G12R low-grade serous ovarian cancer (LGSOC), and <i>KRAS</i> G12C and <i>TP53</i> R181P lung adenocarcinoma (LADC).
Three PDXs were selected for their lack of PTEN expression by immunohistochemistry: a triple-negative breast cancer (TNBC), a <i>KRAS</i> G12R low-grade serous ovarian cancer (LGSOC), and <i>KRAS</i> G12C and <i>TP53</i> R181P lung adenocarcinoma (LADC).
Three PDXs were selected for their lack of PTEN expression by immunohistochemistry: a triple-negative breast cancer (TNBC), a <i>KRAS</i> G12R low-grade serous ovarian cancer (LGSOC), and <i>KRAS</i> G12C and <i>TP53</i> R181P lung adenocarcinoma (LADC).